1995
DOI: 10.1055/s-0038-1653833
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of the Pharmacokinetic Profiles of Three Low Molecular Mass Heparins – Dalteparin, Enoxaparin and Nadroparin – Administered Subcutaneously in Healthy Volunteers (Doses for Prevention of Thromboembolism)

Abstract: SummaryThe present trial was designed to comparatively investigate the pharmacokinetic profile and evaluate the apparent bioavailability pattern of three already marketed low molecular mass heparins (LMMHs): dalteparin (Fragmin®), nadroparin (Fraxiparin®), and enoxaparin (Love- nox®) given by subcutaneous route. The study was carried out in 20 healthy young volunteers given, according to a cross over design, a single subcutaneous injection of the doses recommended for the prophylaxis of deep vein thrombosis (c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

13
116
2
11

Year Published

2000
2000
2022
2022

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 170 publications
(142 citation statements)
references
References 38 publications
13
116
2
11
Order By: Relevance
“…In a direct comparison of three LMWHs, enoxaparin was found to provide the fastest peak of anti Xa activity, the highest bioavailability, and the longest duration of anti Xa activity after SC injection compared with dalteparin and nadroparin. 24) But still the question remains as to whether these pharmacological differences translate into differ- To our knowledge, our study is the first to head-to-head compare two different LMWH molecules in the setting of UA/NQMI. We chose to compare two LMWHs with considerably different anti Xa : anti IIa ratios, enoxaparin at one end and dalteparin at the other.…”
Section: Discussionmentioning
confidence: 93%
“…In a direct comparison of three LMWHs, enoxaparin was found to provide the fastest peak of anti Xa activity, the highest bioavailability, and the longest duration of anti Xa activity after SC injection compared with dalteparin and nadroparin. 24) But still the question remains as to whether these pharmacological differences translate into differ- To our knowledge, our study is the first to head-to-head compare two different LMWH molecules in the setting of UA/NQMI. We chose to compare two LMWHs with considerably different anti Xa : anti IIa ratios, enoxaparin at one end and dalteparin at the other.…”
Section: Discussionmentioning
confidence: 93%
“…In STEMI, the immediate upstream and standard application of GPI improves coronary patency after angiography but has not been proven to be superior to periprocedural treatment in terms of clinical outcome, although a nonsignificant trend towards an improved clinical outcome was seen in some trials. 13,14 Additionally, superiority in cost-effectiveness of either strategy remains unclear. Few trials have addressed this issue and clinical trials assessing cost-effectiveness should be interpreted with care as these trials often encompass a selected patient population.…”
Section: Dose Adjustment For Patients With Renal Failure or Aged Overmentioning
confidence: 99%
“…Primary objectives were peak anti-Xa levels and adjusted anti-Xa levels, adjustment being carried out for dose and body weight. Results: A total of 42 patients could be analyzed during a median of 10 days (interquartile range IQR 4-13, range [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. In all groups, adjusted peak anti-Xa levels were not different on day 10 compared with day 1.…”
Section: )2mentioning
confidence: 99%